Moreover, our MS and non-MS pathological samples displayed a significantly lower enrichment of CD63+ EVs in CSF and CD81+ EVs in serum, and a higher percentage of double-positive CD81+/CD9+ EVs in CSF and CD63+/CD9+ in serum. Here, CD63 is linked to myeloid sarcoma.